Immunovaccine Signs Research Agreement with OncoTherapy Science

Peptide antigens hold the promise of high efficacy and low toxicity. Yet the impact of peptides as an effective means for cancer treatment has been limited, mainly due to the low immunogenicity of peptides. OncoTherapy Science's novel cancer peptides have the potential to function as unique targets for the anti-angiogenic therapy of cancer. The advantage of developing a vaccine formulation using Immunovaccine's DepoVax™ delivery platform is its ability to generate a depot effect that enhances the immunogenicity of peptides in preclinical models.

"We are pleased to be collaborating with OncoTherapy Science and evaluating how our DepoVax™ technology may enhance the potential of these select peptide antigens to create a highly potent, highly specific vaccine candidate," remarked Dr. Marc Mansour, Vice President of R&D at Immunovaccine.